Clinical Trials

Inclusion Criteria:

- Participants must have one of the following histologically or cytologically confirmed
locally advanced unresectable or metastatic solid tumor types:

- High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or
fallopian tube cancer

- HER2-negative, HR positive breast cancer

- Triple-negative breast cancer (TNBC)

- Endometrial carcinoma

- Non-small cell lung cancer (Squamous cell carcinoma [SqCC], Adenocarcinoma [AC])

- Cholangiocarcinoma or gallbladder carcinoma

- Adenoid cystic carcinoma (ACC) of the head and neck

- Parts A and B: Participants must have disease that is relapsed or refractory or be
intolerant to SOC therapies, and, in the judgement of the investigator, should have no
appropriate SOC therapeutic option

- Part C: Participants must have disease that is relapsed or refractory or be intolerant
to SOC therapies, unless contraindicated

- Tumor tissue is required for enrollment.

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Measurable disease per RECIST version 1.1 at baseline

Exclusion Criteria:

- History of another malignancy within 3 years before the first dose of study drug. Any
evidence of residual disease from a previously diagnosed malignancy. Exceptions are
malignancies with a negligible risk of metastasis or death.

- Known active central nervous system metastases. Participants with previously treated
brain metastases may participate provided they:

- are clinically stable for at least 4 weeks prior to study entry after brain
metastasis treatment

- have no new or enlarging brain metastases

- and are off corticosteroids prescribed for symptoms associated with brain
metastases for at least 7 days prior to the first dose of study treatment.

- Carcinomatous meningitis

- Previous receipt of an MMAE-containing agent or an agent targeting B7-H4

- Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) Version 5.0

- Corneal disease or injury requiring treatment or active monitoring

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 5/2/23. Questions regarding updates should be directed to the study team contact.